Drug news
NICE confirms rejection of Abraxane (nab-paclitaxel) for pancreatic cancer- Celgene
The National Institute for Health and Care Excellence (NICE) confirmed that it does not accept Abraxane (nab-paclitaxel) from Celgene for treatment of pancreatic cancer in England and Wales as its benefits are not justified by its costs. NICE commented that though Abraxane was more effective than gemcitabine, it produced more serious side effects and more adverse events than the combination of gemcitabine + capecitabine. The drug will therefore not be available through the Cancer Drugs Fund.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.